Evidence map›Paper›PMID 29216683›Full record

ArticleMolecular genetics & genomic medicine2018

Human perforin gene variation is geographically distributed.

Robin C Willenbring, Yasuhiro Ikeda, Larry R Pease, Aaron J Johnson

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Genetics of Primary Hemophagocytic Lymphohistiocytosis.Advances in experimental medicine and biology · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. 9-Gene Signature Correlated With CD8Frontiers in immunology · 2021
    Article
  7. Human perforin gene variation is geographically distributed.Molecular genetics & genomic medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Robin C WillenbringMayo Clinic Graduate School of Biomedical Sciences, College of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-2138-2912
Yasuhiro IkedaDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Larry R PeaseDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
Aaron J JohnsonDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

CD8 T cell mediated disruption of Blood Brain Barrier Tight JunctionsR01NS103212 · NINDS · MAYO CLINIC ROCHESTER · PI Aaron J Johnson · 2017 to 2026
$4.6M
CD8 T cell mediated disruption of Blood Brain Barrier Tight JunctionsR56NS094150 · NINDS · MAYO CLINIC ROCHESTER · PI JOHNSON, AARON J · 2016 to 2016
$398k
NINDS NIH HHS R01 NS103212NINDS NIH HHS R56 NS094150
6 · The paper itself

Abstract

backgroundDeleterious mutations in PRF1 result in lethal, childhood disease, familial hemophagocytic lymphohistiocytosis type 2 (FHL 2). However, not all mutations in PRF1 are deleterious and result in FHL 2. Currently, these nondeleterious mutations are being investigated in the onset of numerous disorders, such as lymphomas and diabetes. Yet, there is still an overwhelmingly large amount of PRF1 mutations that are not associated with disease.

methodsWe conducted a post hoc analysis of the PRF1 mutations in the coding region using the recently published Exome Aggregation Consortium genomes, Leiden Open Variation Database, NCBI SNP database, and primary literature to better understand PRF1 variation in the human population.

resultsThis study catalogs 460 PRF1 mutations in the coding region, and demonstrates PRF1 is more variant then previously predicted. We identify key PRF1 mutations with high allelic frequency and are only found in certain populations. Additionally, we define PRF1 SNVs are geographically distributed.

conclusionsThis study concludes with a novel hypothesis that nondeleterious mutation in PRF1, which decreases perforin expression and/or activity, may be an example of selective advantage in the context of environmental stressors prevalent near the equator. Our studies illustrate how perforin deficiency can be protective from injuries resulting in blood-brain barrier (BBB) disruption.

Indexed as

AllelesAmino Acid SequenceDatabases, Nucleic AcidEthnicityGene FrequencyGenetic VariationGeographyHumansMutationMutation, MissensePerforinPore Forming Cytotoxic ProteinsPerforinPore Forming Cytotoxic ProteinsPRF1 protein, humanfamilial hemophagocytic lymphohistiocytosis type 2human geneticspathogenperforin

Identifiers

PMID29216683
PMCPMC5823683
OpenAlexW2772486522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.